Trigemina, a pharmaceutical maker working on therapies for acute and chronic pain, has brought in $305,000 of an anticipated $999,000 round of equity and rights, according to a filing with the SEC. Based in Mountain View, Calif., the company is backed by grants from the National Institutes of Health, as well as equity from private sources.
Buy This Item: [Click here to buy this item]